SULFONYLUREA THERAPY DOUBLES B-CELL RESPONSE TO GLUCOSE IN TYPE-2 DIABETIC-PATIENTS
SULFONYLUREA THERAPY DOUBLES B-CELL RESPONSE TO GLUCOSE IN TYPE-2 DIABETIC-PATIENTS
复制标题
DOI：
10.1007/bf00291069
复制
发表时间：
1985-01-01
期刊：
影响因子：
8.2
通讯作者：
TURNER, RC
中科院分区：
文献类型：
--
作者：
HOSKER, JP;BURNETT, MA;TURNER, RC
研究了磺脲类药物治疗3周对2型糖尿病患者葡萄糖刺激的胰岛素分泌和胰岛素抵抗的影响。将单独饮食的空腹血浆胰岛素和C肽浓度与每例受试者在较低空腹血糖和通过高血糖钳夹技术获得的原始单独饮食血糖水平下接受磺脲类药物治疗的空腹浓度进行比较。在此等血糖水平（平均11 mmol/l）下，血浆胰岛素水平从单独饮食的6.9 mU/l增加到磺脲类药物治疗的12.1 mU/l（p<0.01）。受试者在磺脲类药物治疗前和治疗后的平均血药浓度为13 mmol/l时，也采用高血药钳夹技术进行研究;胰岛素反应增量也同样从7.6±3.5 mU/l增加到13.7±6.9 mU/l（p<0.02）。磺脲类药物似乎通过增强B细胞功能2倍来降低血小板减少症。在研究的患者中，这是正常反应的约21%至37%。胰岛素抵抗评估相同的高血压钳夹内源性血浆胰岛素浓度除以葡萄糖输注率是不变的磺脲类药物治疗（平均4.37相比，4.40 mU。1 - 1·mg-1·kg·min（单独饮食）。
The effect of sulphonylurea therapy for 3 weeks on glucose-stimulated insulin secretion and insulin resistance was studied in Type 2 diabetic patients. The fasting plasma insulin and C-peptide concentrations on diet alone were compared with each subject's fasting concentrations on sulphonylurea treatment at a lower fasting plasma glucose and at the original diet-alone glycaemic level obtained by the hyperglycaemic clamp technique. At this isoglycaemic level (mean 11 mmol/l), plasma insulin levels increased from 6.9 mU/l on diet alone to 12.1 mU/l on sulphonylurea treatment (p<0.01). The subjects were also studied by the hyperglycaemic clamp technique at mean glycaemic levels of 13 mmol/l before and after sulphonylurea treatment; the incremental insulin response was similarly enhanced from 7.6±3.5 to 13.7±6.9 mU/l (p<0.02) respectively. Sulphonylureas appear to reduce glycaemia by enhancing B-cell function two-fold. In the patients studied this was from approximately 21% to 37% of a normal response. Insulin resistance assessed by the same hyperglycaemic clamps as endogenous plasma insulin concentrations divided by glucose infusion rates was unchanged by sulphonylurea therapy (mean 4.37 compared to 4.40 mU. 1−1·mg−1·kg·min on diet alone).